Eligiblity For Retatrutide

Who may be eligible for retatrutide?

During phase 2 trials, Retatrutide demonstrated significant reductions in hemoglobin A1C levels among individuals with type 2 diabetes over a span of six months. Simultaneously, those with obesity or excess weight experienced a remarkable body weight reduction of approximately 24% within a year. Dr. Alvarez expressed optimism, stating, “If these findings can be replicated, it’s highly probable that Retatrutide will receive FDA approval for both weight loss and type 2 diabetes.” However, he cautioned that the confirmation of these outcomes would necessitate the results of phase 3 trials.

Eli Lilly is presently in the process of enrolling participants for phase 3 trials of Retatrutide, with an anticipated duration until 2025. Dr. Alvarez further explained, “If these trials progress successfully, it’s probable that Retatrutide will become accessible to individuals with type 2 diabetes, as well as to individuals classified as obese with a BMI of 30 or higher, or those with a BMI of 27 who already experience health issues related to weight.” These eligibility criteria would align with the existing guidelines applied to similar medications.

Dr. Alvarez acknowledged the unpredictability of the FDA approval process, as the agency may request additional information about a drug before granting approval, leading to potential delays. At present, he estimated that Retatrutide might potentially reach the market in late 2026 or early 2027, emphasizing that this projection represents an informed estimate.


At Patients Medical, we strive to provide a range of services and programs that can assist you in losing weight rapidly and healthily. Our doctors will develop a personalized treatment plan for you that could include prescription medication with traditional, alternative, and holistic treatments as well as suggestions for dietary and lifestyle modifications.